Matrix Metalloproteinase Inhibitor MMI270

Preferred Label : Matrix Metalloproteinase Inhibitor MMI270;

NCIt synonyms : MMI 270B CGS27023A; N-hydroxy-2(R)-[[4- methoxysulfonyl](3-picolyl)amino]-3-methylbutaneamide hydrochloride; N-hydroxy-2(R)-[(4-methoxysulfony) (3-picolyl)-amino]-3-metylbutaneamide hydrochloride monohydrate; MMI270;

NCIt related terms : (2R)-N-Hydroxy-2-[[(4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)amino]-3-methylbutanamide Monohydrochloride;

NCIt definition : An orally-active synthetic hydroxamic acid derivative with potential antineoplastic activity. MMI270 inhibits a broad spectrum of matrix metalloproteinases (MMPs) (specifically MMP-1, 2, 3, 9, and 13), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. This agent may also downregulate lymphangiogenesis, resulting in decreased lymphatic system-related metastasis. (NCI04);

Molecule name : CGS27023A; CGS27023;

Codes from synonyms : 50589;

Détails

Origin ID

C2045;

UMLS CUI

C4764295;

Automatic exact mappings (from CISMeF team)
- CGS 27023A [MeSH Supplementary Concept]
- MMI270 [MeSH concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- MMI270 [MeSH concept]
concept_is_in_subset
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients